Stocks Health care AKTX
NASDAQ · Health careAkari Therapeutics Plc (AKTX)
It posted a net loss of $31M. At June 30, 2026 it held $7.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Akari Therapeutics Plc
- Net worth
- Akari Therapeutics Plc has a market value (market cap) of $14.5M at the latest share price, and shareholders' equity of $18.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $10.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Akari Therapeutics Plc's next report was expected around November 6, 2026 and is not on file with the SEC yet.
What Akari Therapeutics Plc does
Akari Therapeutics Plc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AKTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$17.3M | $0.00 | n/a |
| 2024 | n/a | -$19.8M | $0.00 | n/a |
| 2023 | n/a | -$10M | $0.00 | n/a |
| 2022 | n/a | -$17.7M | $0.00 | n/a |
| 2021 | n/a | -$17.4M | $0.00 | n/a |
| 2020 | n/a | -$17.1M | -$0.01 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Akari Therapeutics Plc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 1, 2026Proxy statement DEF 14A
- October 1, 2026Executive or director change8-KAkari Therapeutics amended its CEO agreement to increase executive compensation and equity grants.
- August 13, 2026
- August 13, 2026
- August 12, 2026Passive stake (5% or more) SCHEDULE 13G
- August 7, 2026Passive stake (5% or more) SCHEDULE 13G
- July 10, 2026
- July 8, 2026
- July 2, 2026
- July 2, 2026
Insider trades
What the people running Akari Therapeutics Plc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 29, 2026 | Gaslightwala AbizerCEO, Director | Received as pay | 6,430 | $62.5K |
| August 17, 2026 | Farag Kameel D.Interim CFO | Received as pay | 1,728 | $13K |
| July 16, 2026 | Farag Kameel D.Interim CFO | Received as pay | 1,130 | $13K |
| July 7, 2026 | Patel Samir RashmikantDirector, 10% owner | Exercised optionsindirect | 1,209 | $9.7K |
| July 7, 2026 | Patel Samir RashmikantDirector, 10% owner | Exercised optionsindirect | 15,466 | $6.2 |
| July 7, 2026 | Patel Samir RashmikantDirector, 10% owner | Exercised optionsindirect | 5,799 | $2.3 |
| June 24, 2026 | Farag Kameel D.Interim CFO | Received as pay | 1,248 | $12.5K |
| June 24, 2026 | Farag Kameel D.Interim CFO | Received as pay | 1,395 | $13K |
Who owns AKTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Hoyoung Huh, M.D., Ph.D.13G, passive | 18.4% | March 4, 2026 |
| Samir R. Patel13D, may seek influence | 10.4% | March 4, 2026 |
| Charles Steve Theofilos, M.D.13D, may seek influence with 1 related filers | 9.99% | June 18, 2024 |
| Ray Prudo, M.D.13D, may seek influence with 2 related filers | 8.9% | March 4, 2026 |
| MMCAP International Inc. SPC13G, passive with 1 related filers | 8% | June 8, 2026 |
| White Lion Capital LLC13G, passive | 5% | August 7, 2026 |
Largest institutional holders
Insiders
3 insiders reported holding 135,657 shares in total, about $1M at the last price.
| Holder | Shares |
|---|---|
| Patel Samir RashmikantDirector, 10% owner | 98,24198,241 held indirectly |
| Farag Kameel D.Interim CFO | 23,309 |
| Gaslightwala AbizerCEO, Director | 14,107 |
Questions about AKTX
What does Akari Therapeutics Plc do?
Akari Therapeutics Plc is a company in the Health care sector, listed on NASDAQ as AKTX. Its shares trade on NASDAQ under the ticker AKTX.
What is Akari Therapeutics Plc's net worth?
Akari Therapeutics Plc has a market value (market cap) of $14.5M at the latest share price, and shareholders' equity of $18.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Akari Therapeutics Plc profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $31M.
When did Akari Therapeutics Plc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the proxy statement from October 1, 2026.
When is Akari Therapeutics Plc's next earnings report?
Akari Therapeutics Plc's next report was expected around November 6, 2026 and is not on file with the SEC yet.
Similar companies
Compare AKTX with
Follow AKTX
Get an email when Akari Therapeutics Plc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Akari Therapeutics Plc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.